The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The facility will manufacture its Herceptin biosimilar, Tuznue
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Subscribe To Our Newsletter & Stay Updated
